There is evidence that PD-1 axis blockade can increase antigen-specific antibody secretion [26] or reduce regulatory B cell function [27], supporting the hypothesis that these therapies could augment anti-tumor B cell responses. The gene discussed is PDCD1; the disease is neoplasm.